Aptevo Therapeutics to Present CD40 Platform Data at SITC 2026
Aptevo Therapeutics, Inc. (APVO) will present research on its multispecific CD40-directed platform at SITC 2026 in Phoenix, scheduled for November 4 to 8. Presenter Michelle Nelson, PhD, will share details from Abstract No. 1060 regarding tumor-directed antibody-like molecules. Shares of Aptevo Therapeutics dropped 5.79% to $1.73 in recent trading.
The upcoming presentation centers on combining innate and adaptive immune activation directly inside the tumor microenvironment. By concentrating CD40 activation on cancer cells, Aptevo aims to overcome immune suppression while limiting systemic immune activation throughout the rest of the body.
Investors and industry observers can access additional information following the conference, as the company plans to publish its presentation slides on its website's Publications page after the event ends.
Key points
- Aptevo Therapeutics, Inc. (APVO) will showcase its multispecific CD40 platform at SITC 2026 in Phoenix from November 4 to 8.
- Michelle Nelson, PhD, will present Abstract No. 1060 on tumor-directed antibody-like molecules.
- The platform aims to trigger innate and adaptive immunity within tumors while restricting systemic immune side effects.
- Shares of Aptevo Therapeutics fell 5.79% to $1.73 in recent market activity.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
When will Aptevo Therapeutics present at SITC 2026?
Aptevo Therapeutics will present at SITC 2026 in Phoenix from November 4 through November 8.
What is the focus of Aptevo's SITC 2026 presentation?
The presentation focuses on Aptevo's multispecific CD40 platform, which aims to activate innate and adaptive immunity inside tumors to limit systemic immune activation.
Who is presenting Aptevo's research at SITC 2026?
Michelle Nelson, PhD, will present Abstract No. 1060 on leveraging multispecific antibody-like molecules.